Archives of Medical Research
Volume 40, Issue 6 , Pages 514-524 , August 2009

Impact of a Quadrivalent HPV6/11/16/18 Vaccine in Mexican Women: Public Health Implications for the Region

  • Eduardo Lazcano-Ponce

      Affiliations

    • Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
    • Corresponding Author InformationAddress reprint requests to: Dr. Eduardo Lazcano-Ponce, Director del Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Avenida Universidad 655, Colonia Sta. Ma. Ahuacatitlán. Cuernavaca, Morelos 62508, México; Phone: (+52) (777) 3293003; FAX: (+52) (777) 3111148
    • ,
  • Gonzalo Pérez

      Affiliations

    • Merck and Co. Inc., West Point, PA
    • ,
  • Aurelio Cruz-Valdez

      Affiliations

    • Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
    • ,
  • Laura Zamilpa

      Affiliations

    • Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
    • ,
  • Carlos Aranda-Flores

      Affiliations

    • Servicio de Oncología, Instituto Nacional de Perinatología, México, D.F., Mexico
    • ,
  • Pilar Hernández-Nevarez

      Affiliations

    • Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
    • ,
  • Jose Luis Viramontes

      Affiliations

    • PPD Mexico, S.A. de C.V, México, D.F., Mexico
    • ,
  • Joaquín Salgado-Hernández

      Affiliations

    • Centro Médico Universitario, Universidad Autónoma del Estado de Morelos, Morelos, México
    • ,
  • Margaret James

      Affiliations

    • Merck and Co. Inc., West Point, PA
    • ,
  • Shuang Lu

      Affiliations

    • Merck and Co. Inc., West Point, PA
    • ,
  • Carlos Sattler

      Affiliations

    • Merck and Co. Inc., West Point, PA
    • ,
  • Richard M. Haupt

      Affiliations

    • Merck and Co. Inc., West Point, PA
    • ,
  • Mauricio Hernández-Avila

      Affiliations

    • Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
    • Secretaría de Salud, México, D.F., México

Received 29 June 2009 ,Accepted 8 July 2009.

References 

  1. Murillo R, Almonte M, Pereira A, et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine. 2008;26(suppl 11):L37–L48
  2. Palacio-Mejia L, Lazcano-Ponce E, Allen-Leigh B, et al. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Salud Pública Méx. 2009;51(suppl 2):208–219
  3. Herbert A, Anshu Gregory M, et al. Invasive cervical cancer audit: a relative increase in interval cancers while coverage increased and incidence declined. BJOG. 2009;116:845–853
  4. Vaccarella S, Herrero R, Dai M, et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev. 2006;15:2148–2153
  5. Reyes-Ortiz CA, Velez LF, Camacho ME, et al. Health insurance and cervical cancer screening among older women in Latin American and Caribbean cities. Int J Epidemiol. 2008;37:870–878
  6. Bergström R, Sparén P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer. 1999;81:159–166
  7. Brookfield KF, Cheung MC, Lucci J, et al. Disparities in survival among women with invasive cervical cancer: a problem of access to care. Cancer. 2009;115:166–178
  8. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5:e132
  9. Palacio-Mejía LS, Rangel-Gómez G, Hernández-Avila M, et al. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico. Salud Publica Mex. 2003;45(suppl 3):S315–S325
  10. Lazcano-Ponce E, Palacio-Mejia LS, Allen-Leigh B, et al. Decreasing cervical cancer mortality in Mexico: effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology. Cancer Epidemiol Biomarkers Prev. 2008;17:2808–2817
  11. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19
  12. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26(suppl 10):K29–K41
  13. Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86:140–146
  14. Weisberg E, Bateson D, McCaffery K, et al. HPV vaccination catch up program—utilisation by young Australian women. Aust Fam Physician. 2009;38:72–76
  15. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943
  16. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927
  17. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861–1868
  18. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet. 2007;369:1693–1702
  19. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Theory Meth. 1998;27:1305–1322
  20. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003;10:108–115
  21. Perez G, Lazcano-Ponce E, Hernandez-Avila M, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008;122:1311–1318
  22. Giuliano A, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007;196:1153–1162
  23. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008;26:6844–6851
  24. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743–753
  25. Muñoz N, Franco EL, Herrero R, et al. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008;26(suppl 11):L96–L107
  26. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virologic evidence of HPV infection. J Infect Dis. 2007;196:1438–1446
  27. Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E. A cost-effectiveness analysis of a quadrivalent (HPV 6/11/16/18) human papilloma virus (HPV) vaccine in Mexico. Arch Med Res. 2009;40:503–513
  28. Salmerón J, Lazcano-Ponce E, Lorincz A, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control. 2003;14:505–512
  29. Majewski S, Bosch FX, Dillner J, et al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16–24. J Eur Acad Dermatol Venereol Apr. 2009;23:
  30. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943
  31. Chesson HW, Forhan SE, Gottlieb SL, Markowitz LE. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine. 2008;26:4513–4518
  32. Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2009;74:553–561
  33. Giuliano A, Palefsky J. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men (abstract #SS20). EUROGIN, Nice, France, November 10, 2008.
  34. Palefsky J, Giuliano A. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection in young men (please verify that abstract is same number as reference 33) (abstract #SS-20). EUROGIN, Nice, France, November 13, 2008.
  35. Winkler JL, Wittet S, Bartolini RM, et al. Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean. Vaccine. 2008;26(Suppl 11):L73–L79
  36. Wong LP. HPV information needs, educational messages and channel of delivery preferences: views from developing country with multiethnic populations. Vaccine. 2009;27:1410–1415
  37. Tozzi AE, Ravà L, Stat D, Pandolfi E, Marino MG, Ugazio AG. Attitudes towards HPV immunization of Italian mothers of adolescent girls and potential role of health professionals in the immunization program. Vaccine. 2009;27:2625–2529
  38. Kaufmann AM, Backsch C, Schneider A, Dürst M. HPV induced cervical carcinogenesis: molecular basis and vaccine development. Zentralbl Gynakol. 2002;124:511–524

PII: S0188-4409(09)00134-9

doi: 10.1016/j.arcmed.2009.07.008

Archives of Medical Research
Volume 40, Issue 6 , Pages 514-524 , August 2009

Article Tools

* Image Usage & Resolution